Stock data
BioMarin Pharmaceutical Inc. (BMRN)
BioMarin Pharmaceutical Inc. (BMRN) reported revenue of US$3.22B and net income of US$348.90M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$3.22B | — | US$409.48M | US$348.90M | — |
| 2024 | US$2.85B | — | US$484.21M | US$426.86M | — |
| 2023 | US$2.42B | — | US$185.77M | US$167.65M | — |
| 2022 | US$2.10B | — | US$160.97M | US$141.56M | — |
| 2021 | US$1.85B | — | -US$82.34M | -US$64.08M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$989.71M | US$44.76M | — |
| 2026-03-31 | US$766.21M | US$105.53M | — |
| 2025-12-31 | US$874.57M | -US$46.57M | — |
| 2025-09-30 | US$776.13M | -US$30.74M | — |
| 2025-06-30 | US$825.41M | US$240.53M | — |
| 2025-03-31 | US$745.14M | US$185.69M | — |
| 2024-12-31 | US$747.31M | US$124.94M | — |
| 2024-09-30 | US$745.74M | US$106.08M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.